Cipla launches etanercept biosimilar in India

Cipla Ltd. (Mumbai, India) launched Etacept etanercept in India to treat rheumatic disorders like rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic RA and psoriatic arthritis. The product is a biosimilar version of autoimmune drug Enbrel etanercept, a recombinant p75 tumor necrosis factor (TNF) receptor linked to the Fc portion of human IgG1 (TNFr:Fc) from Pfizer Inc. (NYSE:PFE) and Amgen Inc. (NASDAQ:AMGN). Cipla said Etacept is the first biosimilar to be launched in India and is available at a 30% discount to Enbrel. ...